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1. Introduction 
Assessment of liver histology following orthotopic liver transplantation is an essential 
component of management in the transplant recipient. Most programs recommend liver 
biopsies when there are changes in the patient’s status or biochemical tests. The use of 
protocol allograft biopsies, that is in asymptomatic recipients with normal or near-normal 
liver tests, is controversial. Considerations such as potential morbidity and mortality, cost, 
inconvenience, use of resources, and potential impact of unexplained histopathological 
findings should be weighed against potential individual and societal benefits. More than 
one insult can contribute to late posttransplantation dysfunction and immunosuppression 
can influence the histological findings and the severity of many disease such as recurrent 
viral hepatitis, autoimmune hepatitis (AIH), and rejection. Histological analysis can help to 
determine the main component of injury, but careful clinicopathological correlation is 
needed. Biopsy interpretation should include an assessment of adequacy of the sample, and 
more than 6 portal tracts are considered adequate, a systematic examination, and a 
correlation with clinical aspects such as the original disease, immunosuppression, liver tests, 
viral serology, immunology and radiologic findings. Many transplant units follow center-
specific criteria; however, a wide use of the standardized criteria (Anonymous, 1997; 
Demetris 2000) would enable centers to compare and pool results, improve management, 
and better understand the pathophysiology of disease mechanisms. 
2. Early post-transplant period  
Of the many causes of graft dysfunction in the early posttransplantation period, acute 
allograft rejection, preservation or reperfusion injury, drug-induced liver injury, viral 
infection and bile duct injury are the most common, and a liver biopsy may be required for 
their specific diagnosis and optimal management. The histological changes of 
preservation/reperfusion injury are uncommonly severe and typically resolve during the 
immediate and early posttransplant period. Acute cellular rejection (ACR) normally occurs 
within the first month of transplantation and liver biopsy represents a valuable tool for its 
diagnosis and guiding treatment. Though the histological diagnosis is often straightforward, 
several clinical situations can pose diagnostic challenges, such as patients with co-exiting 
viral hepatitis and other forms of tissue injury. In the early postoperative period, transplant 
recipients receive many drugs that are potentially hepatotoxic, such as antibiotics, 
analgesics, immunosuppressive agents and total parenteral nutrition. Although the 
histological features of drug-induced liver injury are rarely diagnostic, recognition of drug-
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induced graft damage will allow prompt withdrawal. While bacterial and fungal infection 
are often systemic, many viral infections directly affect the graft and usually require 
histology to differentiate infection from rejection and, as the two often co-exist, the 
histological findings will usually guide the need for any change in immunosuppression. The 
two opportunistic viral infections most frequently observed in liver allograft biopsies are 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) (Hubscher, 2006). Other opportunistic 
viral infections that can involve the liver allograft include adenovirus (mainly in pediatric 
liver transplant recipients), herpes simplex virus, varicella zoster virus, and human 
herpesvirus 6 (Kusne, 2006; Ohashi 2008). Most complications of the biliary tree are 
diagnosed radiologically, therefore liver biopsy has a limited role in this setting. Several 
reports have clearly indicated that serum liver tests have poor sensitivity and specificity in 
the diagnosis of graft disfunction. We have found that the extent of changes seen on liver 
histology, evaluated by protocol liver biopsy on the 7th postoperative day and assessed 
using the Banff criteria, has only a weak correlation with the liver tests. Furthermore, the 
change in the liver test is unreliable in predicting the histological severity of graft rejection 
(Neuberger et al., 1998). There is no evidence that patient outcome is improved with use of 
early protocol biopsies. A systematic review of 15 studies including 1566 liver transplant 
recipients showed that 32% of the patients had histologic acute cellular rejection (ACR) on 
protocol biopsy without associated biochemical graft dysfunction; without additional 
treatment, only 14% of these patients subsequently developed biochemical graft 
dysfunction. The authors, therefore, advised against the early protocol biopsy, after 
considering the small but definite risk associated with this procedure, and suggested that 
liver biopsy should be delayed until patients develop biochemical graft dysfunction, 
unexplained fever, or other surrogate markers of rejection or other early graft harmful event 
(Bartlett et al., 2002).  
3. Late post-transplant period  
Allograft biopsies in the late post-transplant period may be done on a protocol basis or as 
part of the diagnostic work-up of patients who are experiencing biochemical or clinical graft 
dysfunction, for monitoring recurrence of disease and response to therapy (e.g. recurrent 
hepatitis C infection). A wide spectrum of histological changes has been reported in the late 
posttransplant period. General classification is difficult as changes may reflect a variety of 
factors including the indications for liver transplant, the center’s policy regarding protocol 
liver biopsies, the consequences of differing  regimens of immunosuppression and 
differences in describing changes. Most of the main complications that occur during the 
early post-transplant period can also be seen in the later period. Changes seen in late post-
transplant biopsies are often complex and may reflect more than one pathological process; 
histology may help to identify the dominant cause of graft damage in such cases.  
Protocol liver biopsies are defined as those biopsies done according to agreed-on guidelines 
and not in response to changes in clinical status or biochemical tests. An informal survey of 35 
transplant units located in North America, Europe, and Australasia, carried out in our unit in 
2007, showed that whereas 65% of units undertake protocol biopsies for patients grafted for 
hepatitis C virus infection, only 25% do so for patients grafted for other indications (Mells, 
2008). Furthermore, protocol biopsies are done less frequently than in the past. The lack of 
consensus regarding the use of protocol liver biopsies is due, in part, to the risks associated 
with the procedure, uncertainty about the usefulness of these biopsies in patients with normal 
liver function tests, costs. Part of the rationale for protocol biopsies was the need to understand 
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the range of histological findings in the ‘normal’ allograft and the histological and clinical 
correlations; it is believed that these changes are now understood (Table 1).  
 
Pros Cons 
Liver tests are associated with poor 
sensitivity and specificity in the diagnosis 
of graft dysfunction and provide little 
information on the severity of graft damage 
Risk of morbidity and mortality associated 
with the procedure 
Protocol liver biopsies are able to detect the 
early stage of many diseases occurring late 
after transplant and allow a early treatment 
that may avoid or delay graft injury and 
graft loss 
The information provided by protocol 
biopsies can be obtained by other means 
Knowledge of the histological changes may 
improve the understanding of the post-
transplant diseases that could improve 
post-transplant care 
Histologic findings often do not influence 
management when liver tests are normal 
and the patient is well 
 High costs 
 Interpretation of the biopsy may be 
jeopardized by differences in 
interpretation between observers 
 Sampling variability 
Table 1. Pros and Cons of a Protocol Biopsy 
Percutaneous liver biopsies carry a risk of morbidity and mortality, that is relatively low, 
however this risk needs to be outweighed by benefits. Early studies reported a rate of major 
complications, represented mostly by bleeding and  infection,  between 0.2% and 1.79%, with a 
mortality rate up to 0.2% (Bubak, 1991; Chezmar, 1991; Lang, 1999; Larson, 1997; Perez Roldan, 
1995; Van Thiel, 1993). The main factors associated with morbidity and mortality after a liver 
biopsy in the immunocompetent patient, such as the presence of a gallbladder or an 
unsuspected abnormal vascular anatomy or dilated bile ducts, generally do not apply to a liver 
transplant recipient; therefore, a lower rate of complication may be anticipated in these 
patients. Whether the presence of a Roux-en-Y choledochojejunostomy is associated with an 
increased risk of septic complication compared with duct-to-duct anastomosis (Ben-Ari, 1996; 
Galati, 1994) is controversial; in our center, as with many other units, a single prophylactic 
dose of antibiotic is given before a percutaneous liver biopsy is performed in recipients with 
Roux loop bilary anastomosis. Liver biopsies are relatively expensive, with a cost estimated at 
USD$1,032 in those without complications and USD$2,745 with complications (Poynard, 2004), 
and where resources are limited, this represents an important argument against a controversial 
diagnostic tool. Furthermore, the reliability of liver histology in making a specific diagnosis; 
this should be evaluated in terms of differences in interpretation between observers, evidenced 
in the assessment of hepatitis C and rejection in allograft biopsies (Demetris, 1991; Netto, 2006), 
and in terms of sampling variability (Maharaj, 1986; Poniachik, 1996; Ratziu, 2005; Regev, 
2002); although studies of sampling variability in liver allograft biopsies have not been 
reported; however this is likely to be similar to that in the native liver. 
The justification for doing protocol biopsies is based on many arguments: 
- Liver tests (LFTs) are associated with poor sensitivity and specificity in the diagnosis of 
graft dysfunction and provide little information on the severity of graft damage;  
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- graft function is better preserved if liver damage is diagnosed and treated early;  
- knowledge of the histological changes in the allograft in different clinical situations may 
result in better understanding of the post-transplant diseases that could improve post-
transplant care. 
There is a  poor correlation between liver tests and histological findings in the late post-
transplant setting. Thus, Berenguer reported that 11 (11.5%) of 97 recipient who were found 
to have abnormal histology at 1-year protocol biopsy had normal liver tests (Berenguer, 
2001). Similar findings were reported with a longer follow-up of 10 years.  Duclos-Valee et 
al, who documented recurrent autoimmune hepatitis in 7 (41%) of 17 patients and reported 
that in 4 (23%) of these patients the histologic findings of disease recurrence on protocol 
allograft biopsies preceded biochemical abnormalities by 1 to 5 years (Duclos-Valla, 2003). 
Sebagh et al evaluated  10-year post-OLT protocol biopsies of 134 patients and calculated 
that the sensitivity and specificity of normal liver tests for the detection of histologic 
abnormalities was only 75% and 54%, respectively.  More recently, Abraham et al. evaluated 
165 protocol allograft biopsies taken from 100 liver transplant patients at the time of normal 
LFTs and normal clinical function and evidenced as a significant fraction of protocol 
allograft biopsies harbor histologic (27%) and clinically significant (11.5%) abnormalities, 
most commonly fatty liver disease, low-grade/low-stage recurrent hepatitis C and primary 
biliary cirrhosis, and central venulitis, including some cases with subsequent fibrosis 
progression (Abraham, 2008) (Table 2). 
 
Study 
Years post-
LT 
Sample 
size 
Patients with 
abnormal 
histology 
[n(%)] 
Patients with 
normal LFTs and 
abnormal 
histology [n(%)] 
Histologic 
findings 
Berenguer 1 231 97 (42%) 11 (11.5%) - 
Duclos-
Vallée 
10 17 7 (41%) 4 (57%) 
Autoimmune 
hepatitis 
Sebagh 10 143 115 (80%) 53 (46%) 
PBC, viral, CH, 
AIH, CR, 
undetermined 
Abraham* 
3 to 8 
months 
(21.8%) 
1 year 
(31.5%) 
2 to 3 years 
(32.7%) 
4 to 5 years 
(13.9%) 
165 44 (27%) 44 (27%) 
Fatty liver 
disease, 
recurrent disease 
(PBC, hepatitis 
C, sarcoidosis), 
Ito cell 
hyperplasia,  
central venulitis, 
mild acute portal 
rejection 
* protocol allograft biopsies were taken at the time of normal LFTs. 
Abbreviations: PBC, primary biliary cirrhosis; CH, chronic hepatitis; AIH, autoimmune hepatitis; CR, 
chronic rejection. 
Table 2. Association between liver tests and histological findings 
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3.1 Hepatitis C  
Another potential indication for protocol liver allograft biopsies is represented by 
recurrence of hepatitis C (rHCV), that is almost universal  following liver transplantation 
(Everhart, 1999). In addition to confirming a diagnosis of rHCV (and excluding other causes 
of graft dysfunction), sequentially liver biopsies are used to assess the need for treatment,  
disease severity and progression. The majority of studies assessing the usefulness of long-
term liver biopsies have been performed in centers with a low prevalence of viral infection, 
and this has led to an underestimation of the clinical importance of this tool. Histological 
abnormalities are often present in protocol biopsies from HCV-positive patients who are 
clinically well with apparently normal graft function (Berenguer, 2001; Sebagh, 2003) and 
these changes may have implications for prognosis and treatment (Roche, 2010). The 
posttransplant course of hepatitis C is associated with a more rapid progression of fibrosis 
than in the native liver, with the development of cirrhosis after 5 years in 28% of cases 
(Samuel, 2006). Early recognition and intervention of recipients with rapidly evolving 
recurrent hepatitis C following orthotopic liver transplantation (OLT) is the only practical 
approach to improve outcome of these patients (Gane, 2008). 
Histologic changes at 1 year, such as fibrosis stage of >2 or an hepatitis activity index 
score>4, predict the subsequent course of recurrent hepatitis C and provide not only an 
early indication of which patients should receive antiviral treatment (Firpi, 2004) but are 
also used to monitor treatment responses (Bahra, 2007). Moreover, diagnosis of HCV-related 
graft cirrhosis before clinical decompensation may facilitate an early referral for liver 
retransplantation at a stage when the probabilities of a favorable outcome are greater. 
Combinations of laboratory test with or without clinical parameters, direct biochemical 
markers of hepatic extracellular matrix turnover, and more complex assays such as 
FibroTest, Fibrometer, and Hepascore, have been evaluated in the non-transplant setting for 
the assessement of progression of fibrosis (Lok, 2005; Leroy, 2004; Imbert-Bismut, 2001; 
Cales, 2005;  Adams, 2005) and have also more recently been used in a similar manner in 
liver allograft recipients (Carrion, 2010; Cholongitas, 2010). Some authors have recently 
developed a model, the FibroTransplant score, based on the presence/absence of HCV 
infection, time since transplant, alpha 2-macroglobulin, AP, total protein, INR, and glucose -  
1/(1+EXP{- [-20.5+(0.99 x presence of HCV infection)+(0.008 x time since LT) + (0.096 x total 
protein) + (6.36 x international normalized ratio [INR]) x (0.277 x glucose) + (0.007 x alkaline 
phosphatase [AP]) + (0.97 x alpha 2-macroglobulin)]}) - which accurately distinguished patients 
with mild to moderate fibrosis from those with advanced fibrosis (Beckebaum, 2010). As 
fibrosis progresses, total protein decreases, whereas INR and the concentration of the 
protease inhibitor alpha 2-macroglobulin increase; moreover, elevated alkaline phosphatase, 
HCVinfection and diabetes have been described as risk factors for progression to severe 
fibrosis (Berenguer, 2000; Syn, 2007). The optimal cutoff value for diagnosis of F>3 was 0.55, 
with a specificity of 90.2%, a sensitivity of 61.8%, a positive predictive value (PPV) of 77.2% 
and a negative predictive value (NPV) of 81.4%. Recently, Berres et al have shown as early 
serum levels of chemokines CXCL10 (interferon-inducible protein 10) independently predict 
the progression of liver fibrosis after LT for HCV infection (Berres, 2011). The most 
promising tool for non-invasive assessement of fibrosis progression in recurrent hepatitis C 
is the transient elastography; this is a reproducible technique that assesses liver stiffness, has 
been validated in patients with chronic hepatitis C for the assessment of hepatic fibrosis and 
can identify patients with rapidly progressive hepatitis C in the first year following OLT, 
differentiating them from patients with slowly progressive hepatitis C (Carrion, 2010); 
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however liver stiffness measurement (LSM) seems to be less reliable in the intermediate 
stages of fibrosis (Beckebaum, 2010), as already reported in the non-transplant setting 
(Foucher, 2006; Ganne-Carrie, 2006). These noninvasive methods, however, should be 
interpreted with caution in the transplant population as there are other possible causes of 
graft fibrosis, there may be atypical features, some related to the effects of 
immunosuppression such as fibrosing cholestatic hepatitis (FCH), and there may be a 
combination of hepatitis C recurrence and graft rejection, that cannot be detected unless a 
liver biopsy is performed. It is likely that non invasive methods will lead to a changing role 
for liver biopsy in the assessment of allograft damage in HCV-positive patients. These are 
not expected to replace liver biopsy in the immediate future, however currently they 
represent an additional tool capable to reduce the frequencies of biopsies for monitoring 
fibrotic changes during follow-up in selected populations, such as patients under 
anticoagulative therapy, with coagulopathy, or those declining a biopsy.  
Patients undergoing liver transplantation for reasons other than HCV have not a strict need 
to undergo protocol liver biopsies. However, abnormal histological findings among non-
HCV+ve recipients with normal aminotransferase levels are not uncommon (Ayata, 2000; 
Mells, 2009; Pappo, 1995; Slapak, 1997); the histological assessment of the graft using 
protocol biopsies in this setting may be helpful in improving the management of these 
patients. The more important histologic abnormalities other than HCV recurrence that may 
be revealed by protocol liver allograft biopsy are reported below. 
3.2 Chronic rejection 
Chronic rejection (CR) is a rare condition that affects the liver graft with a prevalence of 1-
2% but it can lead to graft loss within the first 12 months of transplantation (Hubscher, 2007; 
Sebagh, 2003). It is characterized by obliterative arteriopathy leading to loss of medium-
sized arteries, ischemic cholangiopathy, and progressive loss of interlobular and septal bile 
ducts extent to more than 50% of portal tracts (Demetris, 1998). However, duct loss can be 
patchy in distribution and the assessment of bile duct numbers should be interpreted with 
caution, particularly in small biopsies with fewer than 10 portal tracts. Improvements in 
immunosuppression have resulted, not only in a reduced prevalence of graft failure from 
CR , but also in a different pattern of presentation. More cases now occur later (> 12 months 
post transplant) with a more insidious presentation and an indolent course, in some cases 
running for a period of several years without progressing to graft failure (Nakazawa, 2000; 
Sebagh, 2003). In the early stage of chronic rejection there is a loss of bile ducts in less than 
50% of portal tracts; this is characterized by inflammatory and degenerative changes in bile 
ducts, which have an atrophic or ‘dysplastic-like’ appearance associated with features of 
replicative senescence (Demetris, 2000). Early-stage CR is associated with normal or slightly 
abnormal LFTs and so is detected only by using protocol biopsies; this may be reversible 
simply by altering immunosuppression (IMS) (Wiesner, 1999). However whether the early 
recognition of chronic rejection and a prompt change in IMS have some impact on graft 
survival is an open question. 
3.3 Hepatitis B  
Allograft histology is not as useful in patients transplanted for HBV cirrhosis, as with HCV 
because the virological and serological markers highly reliable for monitoring recurrent 
hepatitis B. However, protocol biopsies may be useful to detect other causes of late allograft 
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dysfunction in patients who received a liver transplant for HBV-related cirrhosis, like 
chronic hepatitis (CH) despite normal liver tests and negative virological markers 
(Targhetta, 2006). 
3.4 Autoimmune hepatitis 
Autoimmune hepatitis (AIH) recurs in up to 30% to 40% of patients after liver 
transplantation (Ayata, 2000; Reich 2000; Vogel 2004;), and if untreated may lead to loss of 
the graft. Protocol biopsies allow early detection of AIH in the allograft because histologic 
changes may precede biochemical disturbance, even by several years (Duclos-Vallee, 2003) 
and therefore a prompt addition or increase in corticosteroid therapy may prevent 
significant injury to the allograft. 
3.5 Cholestatic liver disease 
Primary biliary cirrhosis (PBC) and Primary sclerosing cholangitis (PSC) may recur after 
liver transplantation (Lerut, 1988; Neuberger, 1982), although the impact of recurrent 
disease on long-term survival is controversial. Unlike PSC, liver biopsy represent the gold 
standard for the diagnosis of recurrent PBC with the histological findings of granulomatous 
cholangitis or florid duct lesions, since LFTs and serum AMA after transplant are not 
reliable and it is also important to differentiate recurrent disease  from other causes of bile-
duct damage. Protocol biopsies may provide early signs of recurrence of primary disease, 
and a early use of ursodeoxycholic acid treatment may be beneficial in the long-term, 
although there are no strong evidences supporting this. 
3.6 Chronic hepatitis 
A common histological finding in late allograft liver graft is an unspecified chronic hepatitis 
(CH), defined as a mononuclear portal and lobular infiltrate without features of acute or 
chronic rejection or any other identifiable causes of graft injury (Neuberger, 2005). CH is a 
common finding in late allograft biopsies, occurring in up to 30% to 70% of biopsies taken 
after 12 months and is poorly correlated with the clinical and serologic findings (Hubscher, 
1990; Mells 2009). CH is clinically important because it may be associated with progressive 
fibrosis which may lead to graft cirrhosis (Evans, 2006). In most of the transplant recipients 
CH may be related to identifiable factors such as viral infections, recurrent autoimmune 
diseases, de novo autoimmune hepatitis, fatty liver disease and drug toxicity (Banff 
Working Group, 2006; Brunt, 1999; Haydon, 2002; Hubscher, 2001; Nakhleh, 2005; Pappo, 
1995; Slapak, 1997). However, many patients with CH still do not have any clear cause of 
graft damage. Idiopathic CH may represent a late cellular rejection from suboptimal 
immunosuppression, as suggested by limited evidences (Evans, 2006; Syn, 2007); this may 
justify changes in the IMS and a closer follow-up of these patients.  
3.7 Withdrawal of immunosuppression 
Protocol biopsy may be a useful tool to drive the reduction of immunosuppression after 
transplantation. Some of the major causes of late mortality, such as renal impairment, 
vascular disease, and some de novo malignancies, are clearly related to 
immunosuppression; the absence of significant inflammation or fibrosis in a late protocol 
biopsy may help to identify patients in whom immunosuppression can be safely reduced or 
even withdrawn completely in the hope of achieving “operational tolerance” , with a long-
term benefits for the patient. 
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4. Timing of protocol liver biopsy 
In HCV recipients, fibrosis of the graft progresses since the first year after transplantation 
with a rate of 0.2-0.3 of fibrosis units (FU)/year; the progression seems not to be linear 
during a 10-year follow-up, and may be accelerated in the second half. Therefore, in order to 
monitor the aggressiveness of recurrent disease protocol liver biopsies should be performed 
in those transplanted for HCV-related cirrhosis since the first year from transplant and then 
annually.  
For non-HCV-related transplants, the usual schedule in many centers that undertake 
protocol biopsies is a biopsy at 1, 2 or 3, 5, 10, and 15 years (Mells, 2008); however, there are 
no strong evidences supporting this and the right timing remains to be assessed. 
5. Conclusion 
Protocol allograft liver biopsies represent a useful tool in HCV-recipients for detection and 
follow-up of HCV recurrence. 
The usefulness of long-term protocol liver biopsies in non-HCV liver transplant recipients is 
controversial. They may be useful to detect the early stage of many diseases occurring late 
after transplant, such as chronic rejection or PBC recurrence, and so allow a early treatment 
that may avoid or delay graft injury and graft loss. They may also represent an important 
tool to optimize immunosuppression management  and identify recipients that might be 
successfully weaned. Last but not least, protocol biopsies may offer a better understanding 
of the allograft structure and function. However, clear evidence that these are cost-effective 
and improve patient and graft outcomes is lacking. Further studies are required to devise 
optimal algorithms for the use of liver biopsy in the assessment of the long-term liver 
allograft. 
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